Docs Who Lift

Dr. Spencer Nadolsky and Karl bring on Dr. Austin Baraki and Dr. Jordan Feigenbaum from Barbell Medicine to cut through the peptide hype and explain why most of the research peptides people are currently injecting have no randomized controlled trial data in humans, were abandoned by pharmaceutical companies because they failed or showed harm signals, and may not even contain what is on the label. The core message is simple: calling something a short chain amino acids does not make it safe, natural does not mean studied, and having a standard of evidence before putting something in your body is not being close minded it is basic medicine.

We hear “high cortisol” blamed for everything, but your adrenal glands are supposed to make cortisol in a daily rhythm that helps you wake up, fuel exercise, and handle illness. In this episode, we break down what cortisol actually does, how real adrenal disorders like Cushing’s are diagnosed, and why random at home cortisol tests and “adrenal fatigue” claims are usually misleading.

In this episode, we sit down with leading lactation researcher Dr. Kaytlin Krutsch break down the first real human data on GLP-1 medications in breast milk. She explains what the studies found, what women should consider before starting these medications postpartum, and why the actual risk may be far lower than most people think.

In this episode, Dr. Spencer Nadolsky and Dr. Karl engage with Dr. Susan Davis, a leading endocrinologist and researcher in testosterone therapy for women. They explore the complexities of sexual dysfunction, the role of testosterone in women's health, and the nuances of diagnosing and treating low sexual desire. The conversation delves into the importance of understanding psychosocial factors, the limitations of current testosterone testing, and the appropriate dosing and administration of testosterone therapy. Dr. Davis emphasizes the need for evidence-based practices and the importance of individualized patient care in managing women's sexual health.

Dr. Spencer and Dr. Karl break down the brand-new ACE Obesity Clinical Practice Algorithm, which redefines how clinicians approach obesity as an adiposity-based chronic disease. From de-emphasizing BMI to focusing on personalized health, staging severity, and prioritizing strength training and lifestyle therapy, they unpack what these updates mean for both patients and providers.

Does menopausal hormone therapy change how women respond to GLP-1 medicines like tirzepatide and semaglutide? In this episode, Dr. Spencer Nadolsky and Dr. Karl Nadolsky sit down with Mayo Clinic’s Dr. Maria Daniela Hurtado Andrade and Dr. Regina Castaneda to discuss their latest research, the nuances behind the findings, and what it means for women navigating menopause and obesity care. Do you also want me to generate a few alternative title options that highlight their names (for authority) while still keeping the engagement factor?